< Grace L. Guo MBBS, Ph.D. » EOHSI Directory - EOHSI

Grace L. Guo , MBBS, Ph.D.

Professor Rutgers University – Ernest Mario School of PharmacyEOHSI – Toxicology
Photo of Grace L. Guo MBBS, Ph.D.


Dr. Guo is an Associate Professor at the Department Pharmacology and Toxicology in the Ernest Mario School of Pharmacy of Rutgers University. She is an adjunct faculty of the Department of Pharmacology, Toxicology and Therapeutics in School of Medicine at the University of Kanas Medical Center.  Dr. Guo obtained her MBBS degree from the West China University of Medical Sciences in 1993 and a PhD degree from the University of Kansas Medical Center in 2001, as well as post-doctoral training at the NCI, NIH in 2004. From 2004-2012, Dr. Guo has served as a faculty at the University of Kansas Medical Center.

Research Areas

Liver is essential for life and liver functions are tightly regulated. Particularly, the impact of intestine on liver homeostasis, function and diseases is significant, but this impact has been less studied. Our group has been focusing on determining the effects of intestine-liver crosstalks on liver metabolism and pathogenesis and the underlying molecular mechanisms, especially following disruption of endogenous homeostasis and exposure to xenobiotic chemicals.

Scholarly Activities

  • 2012: Presidential Poster Award, AASLD meeting (2)
  • 2011: Presidential Poster Award, AASLD meeting
  • 2010: Presidential Poster Award, AASLD meeting
  • 2009: Presidential Poster Award, AASLD meeting
  • 2009: Post award winner for Annual Liver Center Symposium, University of Kansas Medical Center
  • 2007: First place in oral presentation in Annual Cancer Center Symposium, University of Kansas Medical Center
  • 2005: BIRCWH/NIH scholar

Recent Publications

  1. Bhattacharya, A, Taylor, RE, Guo, GL. In vivo mouse models to study bile acid synthesis and signaling. Hepatobiliary Pancreat Dis Int. 2023; :. doi: 10.1016/j.hbpd.2023.08.009. PubMed PMID:37620226
  2. Meadows, V, Yang, Z, Basaly, V, Guo, GL. FXR Friend-ChIPs in the Enterohepatic System. Semin Liver Dis. 2023; :. doi: 10.1055/a-2128-5538. PubMed PMID:37442156
  3. Meshanni, JA, Lee, JM, Vayas, KN, Sun, R, Jiang, C, Guo, GL, Gow, AJ, Laskin, JD, Laskin, DL. Suppression of lung oxidative stress, inflammation and fibrosis following nitrogen mustard exposure by the selective farnesoid X receptor agonist obeticholic acid. J Pharmacol Exp Ther. 2023; :. doi: 10.1124/jpet.123.001557. PubMed PMID:37188530
  4. Henry, Z, Meadows, V, Guo, GL. FXR and NASH: an avenue for tissue-specific regulation. Hepatol Commun. 2023;7 (5):. doi: 10.1097/HC9.0000000000000127. PubMed PMID:37058105 PubMed Central PMC10109454
  5. Taylor, R, Armstrong, L, Bhattacharya, A, Henry, Z, Brinker, A, Buckley, B, Kong, B, Guo, G. Myclobutanil-mediated alteration of liver-gut FXR signaling in mice. Toxicol Sci. 2023;191 (2):387-399. doi: 10.1093/toxsci/kfac129. PubMed PMID:36511616 PubMed Central PMC9936201
  6. Murray, A, Banota, T, Guo, GL, Smith, LC, Meshanni, JA, Lee, J, Kong, B, Abramova, EV, Goedken, M, Gow, AJ et al.. Farnesoid X receptor regulates lung macrophage activation and injury following nitrogen mustard exposure. Toxicol Appl Pharmacol. 2022;454 :116208. doi: 10.1016/j.taap.2022.116208. PubMed PMID:35998709 PubMed Central PMC9960619
  7. Jiang, M, Li, F, Liu, Y, Gu, Z, Zhang, L, Lee, J, He, L, Vatsalya, V, Zhang, HG, Deng, Z et al.. Probiotic-derived nanoparticles inhibit ALD through intestinal miR194 suppression and subsequent FXR activation. Hepatology. 2023;77 (4):1164-1180. doi: 10.1002/hep.32608. PubMed PMID:35689610 PubMed Central PMC9741667
  8. Seok, S, Kim, YC, Zhang, Y, Kong, B, Guo, G, Ma, J, Kemper, B, Kemper, JK. Feeding activates FGF15-SHP-TFEB-mediated lipophagy in the gut. EMBO J. 2022;41 (17):e109997. doi: 10.15252/embj.2021109997. PubMed PMID:35686465 PubMed Central PMC9434102
  9. Zhang, L, Guo, GL. Gut-specific inhibition of PPARα as a novel approach of NAFLD treatment. Hepatology. 2023;77 (1):15-17. doi: 10.1002/hep.32592. PubMed PMID:35633082
  10. Guzman, S, Dragan, M, Kwon, H, de Oliveira, V, Rao, S, Bhatt, V, Kalemba, KM, Shah, A, Rustgi, VK, Wang, H et al.. Targeting hepatic kisspeptin receptor ameliorates nonalcoholic fatty liver disease in a mouse model. J Clin Invest. 2022;132 (10):. doi: 10.1172/JCI145889. PubMed PMID:35349482 PubMed Central PMC9106350
Search PubMed
Connections Business Directory | Leaflet | © OpenStreetMap contributors

EOHSI Room 322 Piscataway NJ 08854